1 / 16

RNDr. Vanda Bo štíková , Ph.D .

Diferenciace vakcinačních a divokých kmenů varicella - zoster viru (VZV) pomocí molekulárně biologických metod. RNDr. Vanda Bo štíková , Ph.D. Fylogenetick á analýza založená na genotypizaci celých sekvencí VZV. Loparev et al., J. Virol., Vol. 81, 2007. (rubella).

connie
Download Presentation

RNDr. Vanda Bo štíková , Ph.D .

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diferenciace vakcinačních a divokých kmenů varicella-zoster viru (VZV) pomocí molekulárně biologických metod RNDr. Vanda Boštíková, Ph.D.

  2. Fylogenetická analýza založená na genotypizaci celých sekvencí VZV Loparev et al., J. Virol., Vol. 81, 2007

  3. (rubella)

  4. Globální distribuce VZV - prevalence 70 % a více ve vyznačených oblastech (2011 - E1, E2, M1 – M4, J) Loparev et al., J. Virol., Vol. 78, 2004

  5. VZV Oka live-attenuated vaccine developed 1974 in Japan by Takahashi and others by extensive passage of a clinical isolate named “Oka” through hu and non-hu cells in vitro A series of clinical trials (11 000 healthy adults and children) demonstrated the safety and efficacy of the vaccine in the USA in 1995: approx. 85% of individuals had complete protection Immunity persists for at least 20 years HealthyPeople 2020 goals 2010 90.51% VZV USA

  6. Varicella in Vaccinated PersonsShould we worry about it?

  7. Gomi et al., J. Virol., Vol. 76, 2002

  8. Preliminary genotyping: The implementation of routine universal varicella vaccination in the US created a need to distinguish wild-type infections from vaccine injuries. VZV VZV Genotyping Genotyping Pst Pst - - Pst Pst + + Pst Pst + + Pst Pst +/- - Bgl Bgl + + Bgl Bgl + - Bgl Bgl - + Bgl Bgl + + Msp Msp + + Msp Msp - - Msp Msp - - Msp Msp - - Sma Sma + + Sma Sma - - Sma Sma - - Sma Sma - - Wildtype Japan Wildtype 20% USA WAustralia Africa,Asia Wildtype Europe,EAustralia, 80% US Wildtype Wildtype OKAv Vaccine Wildtype Japanese US Pst-,Bgl- reported from Australia Our lab developed LightCycler real-time PCR hybridization probe-based assays to detect VZV(PCR) and genotype VZV strains based on the presence or absence of a BglI, PstI, or MspI restriction sites within open reading frames (ORFs) 54, 38, and 62, respectively.

  9. Pst+Bgl- Pst+Bgl- Pst+Bgl- Pst+Bgl- 20% Pst+Bgl+ Pst+ Bgl+ Pst-Bgl+=OKAv Pst+Bgl+ Pst-Bgl+ Pst+Bgl+ 37% Pst+Bgl+ Pst+Bgl+ Pst+Bgl-

  10. The differences in the melting temperature of the Sma I ORF62 PCR product discriminate Oka vaccine and wt VZV strains.

  11. ORF 22 : 4 SNPs #37902,38055,38081,38177 VZV genotyp Mosaic Clade C M1 M2 M3 M4 European Clade A or D Japanese Clade B + Clade A (E1) Genotype like DumasC/T ORF 50/ORF 21 #87841/#3725 Clade D (E2) T/C

  12. Loparev et al., Virology, 2008

  13. Virology. 2009 Jan 20;383(2):216-25. Epub 2008 Nov 20. Distribution of varicella-zoster virus (VZV) wild-type genotypes in northern and southern Europe: evidence for high conservation of circulating genotypes. Loparev VN, Rubtcova EN, Bostik V, Tzaneva V, Sauerbrei A, Robo A, Sattler-Dornbacher E, Hanovcova I, Stepanova V, Splino M, Eremin V, Koskiniemi M, Vankova OE, Schmid DS.

  14. Marlene Deleon-Carnes • Antonio Gonzalez • Myron Levin • Stephanie Liffick • Vladimir Loparev • Stanislav Plíšek • Miloslav Salavec • Scott D. Schmid

More Related